Skip links

DMPK and Bioanalysis Studies

Vision of Research (UAE) provides integrated preclinical-to-clinical research services, combining deep expertise in Drug Metabolism and Pharmacokinetics (DMPK) with comprehensive bioanalytical solutions. Our DMPK platform includes metabolic stability assessment, cytochrome P450 (CYP) inhibition/induction studies, metabolite identification, and pathway elucidation across diverse biological systems, including mouse, rat, rabbit, dog, and non-human primates, to ensure translational relevance. These insights are seamlessly supported by our advanced bioanalytical services, which deliver accurate, reproducible, and regulator-ready pharmacokinetic, toxicokinetic, pharmacodynamic, immunogenicity, and bioequivalence data. Together, this integrated approach accelerates the development of small molecules, biologics, vaccines, and biomarker programs by enabling informed decision-making from early discovery through clinical stages.

  • Specialized In Vitro ADME Analysis
  • In Vivo Pharmacokinetic Studies
  • Macromolecule (Biologics) Bioanalysis
  • Small-Molecule Drug Bioanalysis
Send a Message

Request a Call Back

    Veterinary Industry Innovation

    1

    Specialized In Vitro ADME Analysis Services

    Vision of Research (UAE) has extensive experience in laboratory-based pharmacokinetic research, including metabolic stability, cytochrome P450 (CYP) inhibition and induction, metabolic pathway elucidation, and metabolite identification. These studies are conducted using biological systems derived from multiple species, including mouse, rat, rabbit, dog, and non-human primates, ensuring translational relevance. Key In Vitro ADME Services include:

    • Plasma Protein Binding & Stability Testing.
    • Metabolite Prediction & Identification
    • Metabolic Pathway Estimation & Characterization
    • Metabolic Phenotype Investigations & Hepatocyte Stability Assays
    • Liver microsomal metabolism assays
    • CYP450 inhibition assays
    • Membrane transport and permeability assays
    • Drug–drug interaction (DDI) studies

    These assays provide critical early insights into absorption, metabolism, clearance, interaction risks, and human translational potential of drug candidates.

    Veterinary Industry Innovation

    2

    In Vivo Pharmacokinetic Studies

    These comprehensive studies track and analyze the complete journey of a drug within a living organism, from absorption and distribution into tissues (including blood-brain barrier penetration) to its metabolism, excretion, and interactions with other drugs. Using advanced models (such as tumor-bearing animals) and precise techniques (including isotope-labeled compounds), they generate critical quantitative data for optimizing dose selection, formulation effectiveness, and predicting human drug behavior.
    The final goal is to support clinical trial design and ensure a successful transition from preclinical to clinical stages.

    • Tissue distribution studies / Blood–brain barrier penetration
    • In vivo excretion and metabolite identification studies
    • In vivo drug–drug interaction assessments
    • PK/PD studies in tumor-bearing animal models
    • Isotope-labeled compound studies, including tissue distribution and mass balance
    • Formulation and Comparative Bioavailability/Bioequivalence Studies
    • Multiple-Dose & Special Population Pharmacokinetic Studies
    • Pharmacokinetic Modeling and Simulation (PBPK)
    • Dose-Response Studies and Optimal Dose Determination
    Veterinary Industry Innovation

    3

    Macromolecule (Biologics) Bioanalysis

    The Vision of Research Bioanalysis Division specializes in GLP-compliant bioanalytical testing for macromolecular drugs, delivering FDA & NMPA-aligned data that forms the critical foundation for advancing innovative biologics, monoclonal antibodies, vaccines, and biomarker-driven therapies. Our capabilities include:
    • Development, validation and transfer of immune-assay methods
    • Rapid analytical method validation for accelerated timelines
    • Bioanalysis of macromolecular drugs compliant with FDA
    • Support for biologics, monoclonal antibodies, vaccines, and biomarker-driven therapies
    • GLP-compliant services for preclinical and clinical studies
    • Specialized immune-assay development for Antibody-Drug Conjugates (ADCs)
    • Targeted immune-assays for specific monoclonal antibodies
    • (e.g., adalimumab, bevacizumab, trastuzumab, pertuzumab)
    Veterinary Industry Innovation

    4

    Small-Molecule Drug Bioanalysis

     We specialize in complex bioanalytical challenges for small-molecule drugs, offering end-to-end GLP-compliant services that meet FDA/NMPA guidelines. Our solutions ensure accurate pharmacokinetic and safety data to advance your candidates efficiently through preclinical, clinical, and global registration stages. Our services include:

    • Early-stage DMPK/ADME support (in vitro and in vivo)
    • Bioanalysis for pharmacology and toxicology studies
    • Bioequivalence (BE) and bio similarity assessments
    • Analysis of samples from global clinical trials
    • Development and optimization of sensitive LC–MS/MS methods
    • Validation, transfer, and implementation of bioanalytical protocols